Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1033

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to a strategic decision by Novartis to discontinue development of ligelizumab in CSU. This decision was not based on any safety concerns.

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Ligelizumab

Sponsor

Novartis Pharmaceuticals